Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396862 · ClinicalTrials.gov registry record
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 272
- Enrollment target
NCT02396862 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 272 participants.
The verdict
NCT02396862 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 272 participants
- Enrollment target
Study Summary
The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
Interventions
- DRUG Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2018-03-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396862
The ClinicalTrials.gov registry entry for NCT02396862 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) is the first listed.
NCT02396862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02396862 about?
NCT02396862 is a clinical study titled "Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment". The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
What is the current status of trial NCT02396862?
This trial is currently completed. The enrollment target is 272 participants. The study started on 2015-12-09. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT02396862?
The interventions under investigation include: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) (DRUG).
Who is sponsoring clinical trial NCT02396862?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.